Long-term follow-up confirmed the previously reported result that intermittent administration of imatinib is safe and effective in CML patients.
Despite the early trial termination due to safety concerns, an analysis suggests that ponatinib offers improved efficacy over imatinib in newly diagnosed CML.
A new, investigational proteasome inhibitor, oprozomib (Onyx Pharmaceuticals, Inc.), has shown activity in multiple myeloma, including those patients with carfilzomib-refractory disease.
Combining the cyclin-dependent kinase (CDK) inhibitor dinaciclib (SCH 727965) with ofatumumab (Arzerra) resulted in activity in relapsed or refractory chronic lymphocytic leukemia (CLL).
Heavily pretreated multiple myeloma patients responded to treatment with the oral Bruton’s tyrosine kinase (BTK) inhibitor, ibrutinib (Imbruvica) plus dexamethasone in a phase 2, open-label, dose-finding trial.
The addition of daratumumab to traditional therapies used in the treatment of multiple myeloma was well tolerated and associated with high rates of responses.
An oral inhibitor of isocitrate dehydrogenase 2 (IDH2), AG-221, has shown activity and potentially durable remissions in patients with acute myeloid leukemia.
In this video from the 2014 ASH Meeting, Dr. Grupp discusses data from a trial using CAR T-cell therapy in children and young adults with relapsed, treatment-resistant ALL.
A single cycle of blinatumomab resulted in complete minimal residual disease response in 78% of patients with acute lymphoblastic leukemia.
Early consolidation therapy with brentuximab vedotin after autologous stem cell transplant improved progression-free survival of patients with Hodgkin lymphoma.